MX2016008989A - Fragmentos mutantes de ospa y metodos y usos relacionados con estos. - Google Patents
Fragmentos mutantes de ospa y metodos y usos relacionados con estos.Info
- Publication number
- MX2016008989A MX2016008989A MX2016008989A MX2016008989A MX2016008989A MX 2016008989 A MX2016008989 A MX 2016008989A MX 2016008989 A MX2016008989 A MX 2016008989A MX 2016008989 A MX2016008989 A MX 2016008989A MX 2016008989 A MX2016008989 A MX 2016008989A
- Authority
- MX
- Mexico
- Prior art keywords
- ospa
- methods
- mutant fragments
- borrelia infection
- uses relating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Gram-negative bacteria
- C07K16/1207—Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención se refiere a composiciones y métodos para la prevención y el tratamiento de una infección por Borrelia. En particular, la presente invención se refiere a un polipéptido que comprende un fragmento híbrido de extremo C de una proteína A de la superficie externa (OspA), un ácido nucleico que la codifica, un anticuerpo que se une específicamente a esta, una composición farmacéutica (particularmente para su uso como medicamento en un método para tratar o prevenir una infección por Borrelia) que comprende el polipéptido y/o el ácido nucleico y/o el anticuerpo, un método para tratar o prevenir una infección por Borrelia y un método para inmunizar a un sujeto.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14150682 | 2014-01-09 | ||
| PCT/EP2015/050365 WO2015104396A1 (en) | 2014-01-09 | 2015-01-09 | Mutant fragments of ospa and methods and uses relating thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016008989A true MX2016008989A (es) | 2016-10-04 |
| MX369195B MX369195B (es) | 2019-10-31 |
Family
ID=49917594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008989A MX369195B (es) | 2014-01-09 | 2015-01-09 | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US9975927B2 (es) |
| EP (2) | EP3564257B1 (es) |
| JP (1) | JP6505110B2 (es) |
| KR (1) | KR102460165B1 (es) |
| CN (1) | CN105980398B (es) |
| AU (1) | AU2015205520B2 (es) |
| BR (2) | BR122023024315A2 (es) |
| CA (1) | CA2931110A1 (es) |
| CY (1) | CY1121734T1 (es) |
| DK (2) | DK3092246T3 (es) |
| EA (1) | EA034554B1 (es) |
| ES (2) | ES3041237T3 (es) |
| FI (1) | FI3564257T3 (es) |
| HR (2) | HRP20191086T1 (es) |
| HU (2) | HUE072712T2 (es) |
| LT (1) | LT3092246T (es) |
| MX (1) | MX369195B (es) |
| NZ (1) | NZ721015A (es) |
| PL (2) | PL3092246T3 (es) |
| PT (2) | PT3092246T (es) |
| RS (1) | RS59075B1 (es) |
| SI (2) | SI3564257T1 (es) |
| SM (1) | SMT201900383T1 (es) |
| TR (1) | TR201910117T4 (es) |
| WO (1) | WO2015104396A1 (es) |
| ZA (1) | ZA201602690B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| MX369195B (es) | 2014-01-09 | 2019-10-31 | Valneva Austria Gmbh | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. |
| ES2957939T3 (es) | 2017-04-13 | 2024-01-30 | Valneva Austria Gmbh | Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos |
| CN110483624B (zh) * | 2019-08-22 | 2021-02-09 | 中国疾病预防控制中心传染病预防控制所 | 伽氏疏螺旋体OspA蛋白C端肽段及其应用 |
| CN115698044A (zh) * | 2020-04-09 | 2023-02-03 | 瓦尔尼瓦奥地利有限责任公司 | 用于医学用途的包含三种OspA融合蛋白的组合物 |
| US20240026412A1 (en) | 2020-04-09 | 2024-01-25 | Valneva Austria Gmbh | Improved methods of producing a lipidated protein |
| US12228578B2 (en) | 2020-12-17 | 2025-02-18 | Idexx Laboratories, Inc. | Rocky mountain spotted fever detection and treatment |
| JP2025514211A (ja) | 2022-04-25 | 2025-05-02 | ファイザー・インク | ライム病に対する防御免疫応答を誘発するための組成物および方法 |
| EP4580665A2 (en) * | 2022-09-02 | 2025-07-09 | The Medical College of Wisconsin, Inc. | Use of immunogenic t cell epitopes for lyme disease vaccination and diagnosis |
| WO2025015077A1 (en) | 2023-07-10 | 2025-01-16 | Dynavax Technologies Corporation | Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens |
| WO2025015042A1 (en) | 2023-07-10 | 2025-01-16 | Dynavax Technologies Corporation | Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen |
| WO2025212893A1 (en) * | 2024-04-04 | 2025-10-09 | The Medical College Of Wisconsin, Inc. | Compositions and methods for treating and/or preventing lyme disease |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
| US6248562B1 (en) * | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
| PT1311540E (pt) | 2000-08-18 | 2008-03-20 | Univ New York State Res Found | Ospa de borrelia burgdorferi modificada |
| UA89481C2 (uk) | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
| CA2661224A1 (en) | 2006-09-15 | 2008-03-20 | Intercell Ag | Borrelia antigens |
| HUE036180T2 (hu) | 2006-09-26 | 2018-06-28 | Infectious Disease Res Inst | Szintetikus adjuvánst tartalmazó vakcina készítmény |
| CN107641151B (zh) | 2010-05-14 | 2021-10-01 | 百深公司 | Ospa嵌合体及其在疫苗中的用途 |
| TWI507413B (zh) | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
| TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
| US8986704B2 (en) | 2012-07-06 | 2015-03-24 | Valneva Austria Gmbh | Mutant fragments of OspA and methods and uses relating thereto |
| MX369195B (es) | 2014-01-09 | 2019-10-31 | Valneva Austria Gmbh | Fragmentos mutantes de ospa y métodos y usos relacionados con estos. |
| CZ2014320A3 (cs) | 2014-05-09 | 2015-11-18 | VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. | Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy |
| ES2957939T3 (es) | 2017-04-13 | 2024-01-30 | Valneva Austria Gmbh | Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos |
-
2015
- 2015-01-09 MX MX2016008989A patent/MX369195B/es active IP Right Grant
- 2015-01-09 FI FIEP19177679.8T patent/FI3564257T3/fi active
- 2015-01-09 RS RS20190970A patent/RS59075B1/sr unknown
- 2015-01-09 ES ES19177679T patent/ES3041237T3/es active Active
- 2015-01-09 BR BR122023024315-3A patent/BR122023024315A2/pt not_active Application Discontinuation
- 2015-01-09 WO PCT/EP2015/050365 patent/WO2015104396A1/en not_active Ceased
- 2015-01-09 DK DK15703228.5T patent/DK3092246T3/da active
- 2015-01-09 ES ES15703228T patent/ES2740985T3/es active Active
- 2015-01-09 HU HUE19177679A patent/HUE072712T2/hu unknown
- 2015-01-09 SM SM20190383T patent/SMT201900383T1/it unknown
- 2015-01-09 CN CN201580003319.2A patent/CN105980398B/zh active Active
- 2015-01-09 EP EP19177679.8A patent/EP3564257B1/en active Active
- 2015-01-09 HU HUE15703228A patent/HUE043779T2/hu unknown
- 2015-01-09 KR KR1020167015981A patent/KR102460165B1/ko active Active
- 2015-01-09 US US15/110,151 patent/US9975927B2/en active Active
- 2015-01-09 AU AU2015205520A patent/AU2015205520B2/en active Active
- 2015-01-09 TR TR2019/10117T patent/TR201910117T4/tr unknown
- 2015-01-09 EP EP15703228.5A patent/EP3092246B1/en active Active
- 2015-01-09 HR HRP20191086 patent/HRP20191086T1/hr unknown
- 2015-01-09 PL PL15703228T patent/PL3092246T3/pl unknown
- 2015-01-09 PT PT15703228T patent/PT3092246T/pt unknown
- 2015-01-09 SI SI201532073T patent/SI3564257T1/sl unknown
- 2015-01-09 CA CA2931110A patent/CA2931110A1/en active Pending
- 2015-01-09 SI SI201530777T patent/SI3092246T1/sl unknown
- 2015-01-09 JP JP2016541706A patent/JP6505110B2/ja active Active
- 2015-01-09 DK DK19177679.8T patent/DK3564257T3/da active
- 2015-01-09 BR BR112016015678A patent/BR112016015678B1/pt active IP Right Grant
- 2015-01-09 PL PL19177679.8T patent/PL3564257T3/pl unknown
- 2015-01-09 LT LTEP15703228.5T patent/LT3092246T/lt unknown
- 2015-01-09 PT PT191776798T patent/PT3564257T/pt unknown
- 2015-01-09 HR HRP20250954TT patent/HRP20250954T1/hr unknown
- 2015-01-09 EA EA201691095A patent/EA034554B1/ru unknown
- 2015-01-09 NZ NZ721015A patent/NZ721015A/en unknown
-
2016
- 2016-04-19 ZA ZA2016/02690A patent/ZA201602690B/en unknown
-
2018
- 2018-04-04 US US15/944,835 patent/US10766931B2/en active Active
-
2019
- 2019-06-27 CY CY20191100676T patent/CY1121734T1/el unknown
-
2020
- 2020-08-11 US US16/990,023 patent/US11572392B2/en active Active
-
2023
- 2023-01-06 US US18/150,971 patent/US20230322869A1/en not_active Abandoned
-
2025
- 2025-11-12 US US19/386,871 patent/US20260070950A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| NZ703597A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| JOP20200116B1 (ar) | طرق لعلاج أو الوقاية من الصداع النصفي | |
| MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| MX2022005291A (es) | Vacunas para el tratamiento y prevencion del cancer. | |
| MX2014009909A (es) | Acido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilacion para incrementar la expresion de un antigeno tumoral codificado. | |
| EP4316517A3 (en) | Combination therapy against cancer | |
| MY167232A (en) | Polypeptides binding to human complement c5 | |
| PH12018501114A1 (en) | Polypeptides inhibiting cd40l | |
| MX2024003743A (es) | Inmunoglobulinas de union a agrecano. | |
| WO2015067755A3 (en) | Novel methods and antibodies for treating coagulapathy | |
| MY178445A (en) | Novel antibody binding to tfpi and composition comprising the same | |
| WO2015187521A3 (en) | Anti-blys antibodies | |
| SG10201805646WA (en) | Angiopoietin-like 4 antibodies and methods of use | |
| MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| WO2015200768A3 (en) | Pharmacologic treatments of menière's disease | |
| WO2015132103A3 (en) | Polypeptides derived from enterococcus and their use for vaccination and the generation of therapeutic antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |